Literature DB >> 6622110

Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity.

L B Marks, R H Notter, G Oberdorster, J T McBride.   

Abstract

Surface active aerosols were produced from aqueous dispersions of mixed lipids (CLL), extracted from bovine lung lavage. Particle size distributions were measured as a function of humidity for two types of aerosol generators: ultrasonic and jet. Lipid dispersions before aerosolization were prepared by sonication in an ice bath and by mechanical vortexing. Over a range of high humidity greater than 60-70%, ultrasonic nebulization gave CLL aerosols with mass median aerodynamic diameters (MMAD) of 1.4 +/- 0.1 micron, compatible with predicted alveolar deposition fractions of 0.2-0.3 according to current deposition models. For humidities of 30-95%, jet nebulization gave MMAD values of 0.4-0.5 micron, which have lower predicted alveolar deposition. The surface pressure-time (pi - t) adsorption characteristics at 35 +/- 2 degrees C of CLL dispersions prepared initially by vortexing or sonication were not significantly affected by ultrasonic nebulization over a 1-2 h time period. In addition, the dynamic surface tension lowering of both kinds of CLL dispersion was not affected by ultrasonic nebulization (minimum surface tension less than 1 dyne/cm at 37 degrees C and 100% humidity). Current interest in the treatment of the respiratory distress syndrome (RDS) with exogenous surfactant replacement has focused largely on the delivery of surfactant replacement has focused largely on h delivery of surfactants to infants by tracheal instillation at birth. However, the ability to form multi-component surfactant aerosols with appreciable alveolar deposition fractions and high surface activity may help to expand the utility of replacement therapy to patients with aerated lungs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6622110     DOI: 10.1203/00006450-198309000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Delivery of therapeutic aerosols to intubated babies.

Authors:  J Grigg; S Arnon; T Jones; A Clarke; M Silverman
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

2.  Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective.

Authors:  N S Morton
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

3.  Nebulisation of surfactants in an animal model of neonatal respiratory distress.

Authors:  T F Fok; M al-Essa; M Dolovich; F Rasid; H Kirpalani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

Review 4.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

5.  Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).

Authors:  H L Halliday; W O Tarnow-Mordi; J D Corcoran; C C Patterson
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

Review 6.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

7.  Deposition of Aerosolized Lucinactant in Nonhuman Primates.

Authors:  Timothy J Gregory; Hammad Irshad; Ramesh Chand; Philip J Kuehl
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-08-22       Impact factor: 2.849

Review 8.  Pulmonary surfactant as a versatile biomaterial to fight COVID-19.

Authors:  Lore Herman; Stefaan C De Smedt; Koen Raemdonck
Journal:  J Control Release       Date:  2021-11-20       Impact factor: 9.776

9.  Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats.

Authors:  Yu Sun; Rui Yang; Ji-gen Zhong; Feng Fang; Jin-jin Jiang; Ming-yao Liu; Jian Lu
Journal:  Crit Care       Date:  2009-03-04       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.